Outcome of Acute Respiratory Failure Secondary to Engraftment in Children After Hematopoietic Stem Cell Transplant

Conclusion: Our results suggest that children who develop ARF during engraftment have better ICU survival rates than do those with other etiologies of ARF post-HSCT. Furthermore, fluid overload contributes to mortality in these children; therefore, strategies to prevent and address fluid overload should be considered.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: The use of RBC exchange is potentially safe and effective in the management of a case of sirolimus toxicity. PMID: 32888326 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
CONCLUSION: Daily assessment of renal function by GFR, prior each dose of carboplatin during HDC-ASCR, will help in protecting the kidney in heavily treated population of oncology/HSCT patients. Although the study had a small number of patients which is a major limitation of the study, but it points to a serious transplant-related morbidity and mortality. So, larger scale studies are needed to clarify the best approach to carboplatin dosing to insure the optimal balance between efficacy and toxicity. PMID: 32372349 [PubMed - in process]
Source: J Egypt Natl Canc In... - Category: Cancer & Oncology Authors: Tags: J Egypt Natl Canc Inst Source Type: research
Renal impairment is a common problem in patients with multiple myeloma (MM), and approximately 2-3% of patients develop renal impairment requiring dialysis. Autologous stem cell transplantation (ASCT) is a mainstay of treatment for eligible patients. Although dialysis is not a contraindication to ASCT, further data on the safety of ASCT for these patients is needed, especially for patients on peritoneal dialysis (PD) for which there is limited data available.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 353 Source Type: research
AbstractAcute kidney injury (AKI) after hematopoietic stem cell transplantation (HSCT) is associated with high mortality rates. To determine the incidence and risk factors associated with AKI in patients undergoing HSCT during the infusion period, patients admitted for HSCT from 2012 to 2015 were studied. AKI was classified according to the KDIGO (Kidney Disease Improving Global Outcomes) criteria. We analyzed the main comorbidities, underlying conditions, types of transplant, preparative regimens, and use of potentially nephrotoxic drugs as risk factors for AKI. Among the 180 patients (median age 53  years), 69 (36.5...
Source: Annals of Hematology - Category: Hematology Source Type: research
Abstract Hematopoietic stem cell transplantation is a life-saving therapy for many patients with cancer, as well as patients with some nonmalignant hematologic disorders, such as aplastic anemia, sickle cell disease, and certain congenital immune deficiencies. Kidney injury directly associated with stem cell transplantation includes a wide range of structural and functional abnormalities, which may be vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial. AKI occurs commonly after stem cell transplant, affecting 10%-73% of patients. The...
Source: Clinical Journal of the American Society of Nephrology : CJASN - Category: Urology & Nephrology Authors: Tags: Clin J Am Soc Nephrol Source Type: research
ConclusionChemotherapy followed by ASCT using a conditioning regimen of reduced melphalan and pharmacokinetically targeted busulfan is a promising strategy for treating patients with relapsed or refractory DLBCL who also have end-stage renal disease and are receiving hemodialysis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Abstract In the future, stem cell-based technologies may be harnessed to replace conventional dialysis and transplantation in patients with diabetic nephropathy. Recently, there has been considerable effort to improve methods for the differentiation of human pluripotent stem cells (hPSCs) into kidney cells in culture. Here, we present a protocol for obtaining more advanced kidney structures than have currently been possible in vitro, including vascularized glomeruli and tubular elements. HPSCs are first differentiated in 2D culture to a kidney progenitor stage. These cells are then dissociated and injected subcuta...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Tags: Methods Mol Biol Source Type: research
Publication date: Available online 7 November 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Kaoru Morita, Masahiro Ashizawa, Yumiko Toda, Takashi Ikeda, Shin-ichiro Kawaguchi, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo MuroiAbstractAbout 40% of patients with diffuse large B cell lymphoma (DLBCL) relapse after or are refractory to standard chemotherapy with rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednis...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem-cell transplantation (ASCT) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) patients receiving hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a patient with refractory DLBCL with end-stage renal disease and successfully administered adjusted dosing of salvage chemotherapies and a conditioning regimen in ASCT without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
A treatment strategy of salvage chemotherapy and autologous stem cell transplantation in relapsed or refractory DLBCL patients on hemodialysis has not yet been established. We conducted a pharmacokinetic analysis in a refractory DLBCL patient with end-stage renal disease, and successfully administered adjusted dosing of salvage chemotherapies and conditioning regimen in autologous stem cell transplantation without any adverse events.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Cancer & Oncology | Children | Dialysis | Hematology | Intensive Care | Pediatrics | Respiratory Medicine | Stem Cell Therapy | Stem Cells | Study | Transplants